Hsu et al used the TriNetX platform to study the association between semaglutide use and the incidence of NAION and found that it was associated with an increased risk in patients with diabetes at the 2-, 3-, and 4-year timepoints but not within 1 year of GLP-1 RA initiation
When administered by a medical weight loss doctor as part of a comprehensive, personalized weight loss program, Semaglutide (Ozempic, Wegovy) is extremely safe and highly effective
However semaglutide, which is licensed for weight-loss purposes under the brand name Wegovy, has yet to be provided to the NHS by Novo Nordisk, the company that makes the drug
Huang J, Gu M, Lai Z, Fan B, Shi K, Zhou YH, Yu JQ, Chen Z
** Drugs like Ozempic are only expected to continue to rise in popularity